Literature DB >> 31709276

Spillover Effects of the Hospital Readmissions Reduction Program on Radical Cystectomy Readmissions.

Matthew S Lee1, Brent K Hollenbeck1, Mary K Oerline1, Ted A Skolarus1, Bruce L Jacobs2, Rita Jen1, Amy N Luckenbaugh1, Vahakn Shahinian1, Tudor Borza3.   

Abstract

INTRODUCTION AND
OBJECTIVE: Readmission rates after radical cystectomy are among the highest of any surgery. The Hospital Readmissions Reduction Program (HRRP) penalizes hospitals with excess readmissions for certain targeted conditions, including total hip and knee arthroplasty. We examined whether changes made by hospitals in response to the HRRP had spillover effects on radical cystectomy readmissions.
METHODS: We used a 20% sample of Medicare data to identify patients undergoing cystectomy from 2010 to 2014 and measured 30-day adjusted cystectomy readmission rates. To determine the effect of the HRRP, we calculated adjusted readmission rates following total hip or knee arthroplasty and stratified hospitals into quartiles (most improved, middle quartiles, least improved) based on their improvement in reducing those targeted readmissions. Multivariable logistic regression was used to identify factors associated with spillover effects from the targeted joint surgery to cystectomy.
RESULTS: We identified 2,394 patients undergoing radical cystectomy. Of these, 606 were treated at hospitals in the "most improved" quartile and 522 in the "least improved." Patients undergoing cystectomy were similar in age, comorbidity, and SEC independent of hospital performance quartile. The readmission rate following cystectomy was 26% in the most improved quartile and 24% in the least improved. No spillover effect was identified between readmission reduction after major joint surgery and radical cystectomy (adjusted OR 0.90, p=0.42).
CONCLUSIONS: Hospitals that succeeded in reducing readmissions following major joint surgery targeted by the HRRP did not have similar reductions in readmissions following radical cystectomy. This lack of spillover effect suggests that each surgical condition may require tailored interventions to prevent readmissions.

Entities:  

Keywords:  bladder; cancer; readmissions

Year:  2018        PMID: 31709276      PMCID: PMC6839759          DOI: 10.1097/UPJ.0000000000000042

Source DB:  PubMed          Journal:  Urol Pract        ISSN: 2352-0779


  29 in total

1.  Factors contributing to all-cause 30-day readmissions: a structured case series across 18 hospitals.

Authors:  Paul Feigenbaum; Estee Neuwirth; Linda Trowbridge; Serge Teplitsky; Carol Ann Barnes; Emily Fireman; Jann Dorman; Jim Bellows
Journal:  Med Care       Date:  2012-07       Impact factor: 2.983

2.  Influence of post-cystectomy complications on cost and subsequent outcome.

Authors:  Badrinath R Konety; Veerasathpurush Allareddy
Journal:  J Urol       Date:  2007-01       Impact factor: 7.450

3.  No Differences in Population-based Readmissions After Open and Robotic-assisted Radical Cystectomy: Implications for Post-discharge Care.

Authors:  Tudor Borza; Bruce L Jacobs; Jeffrey S Montgomery; Alon Z Weizer; Todd M Morgan; Khaled S Hafez; Cheryl T Lee; Benjamin Y Li; Hye Sung Min; Chang He; Scott M Gilbert; Jonathan E Helm; Mariel S Lavieri; Brent K Hollenbeck; Ted A Skolarus
Journal:  Urology       Date:  2017-03-04       Impact factor: 2.649

4.  Hospitalization trends after prostate and bladder surgery: implications of potential payment reforms.

Authors:  Bruce L Jacobs; Yun Zhang; Hung-Jui Tan; Zaojun Ye; Ted A Skolarus; Brent K Hollenbeck
Journal:  J Urol       Date:  2012-11-16       Impact factor: 7.450

5.  Redefining the implications of nasogastric tube placement following radical cystectomy in the alvimopan era.

Authors:  Vignesh T Packiam; Vijay A Agrawal; Joseph J Pariser; Andrew J Cohen; Charles U Nottingham; Shane M Pearce; Norm D Smith; Gary D Steinberg
Journal:  World J Urol       Date:  2016-07-30       Impact factor: 4.226

6.  Understanding hospital readmission intensity after radical cystectomy.

Authors:  Ted A Skolarus; Bruce L Jacobs; Florian R Schroeck; Chang He; Alexander M Helfand; Jonathan Helm; Michael Hu; Mariel Lavieri; Brent K Hollenbeck
Journal:  J Urol       Date:  2014-11-04       Impact factor: 7.450

7.  Neighborhood of residence and incidence of coronary heart disease.

Authors:  A V Diez Roux; S S Merkin; D Arnett; L Chambless; M Massing; F J Nieto; P Sorlie; M Szklo; H A Tyroler; R L Watson
Journal:  N Engl J Med       Date:  2001-07-12       Impact factor: 91.245

Review 8.  Enhanced Recovery Pathways Versus Standard Care After Cystectomy: A Meta-analysis of the Effect on Perioperative Outcomes.

Authors:  Mark D Tyson; Sam S Chang
Journal:  Eur Urol       Date:  2016-06-11       Impact factor: 20.096

9.  Alvimopan, a peripherally acting μ-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: economic analysis of a phase 4 randomized, controlled trial.

Authors:  Teresa L Kauf; Robert S Svatek; Gilad Amiel; Timothy L Beard; Sam S Chang; Amr Fergany; R Jeffrey Karnes; Michael Koch; Jerome O'Hara; Cheryl T Lee; Wade J Sexton; Joel W Slaton; Gary D Steinberg; Shandra S Wilson; Lee Techner; Carolyn Martin; Jessica Moreno; Ashish M Kamat
Journal:  J Urol       Date:  2013-12-14       Impact factor: 7.450

10.  Risk adjustment of Medicare capitation payments using the CMS-HCC model.

Authors:  Gregory C Pope; John Kautter; Randall P Ellis; Arlene S Ash; John Z Ayanian; Lisa I Lezzoni; Melvin J Ingber; Jesse M Levy; John Robst
Journal:  Health Care Financ Rev       Date:  2004
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.